Drug intelligence / Profile preview

D-BACE

Development stage: Unknown
Modality: Small Molecules
Administration: Intra-arterial

Overview

D-BACE is a drug-eluting bead (DCB) formulation that delivers the anthracycline chemotherapy agent epirubicin. Epirubicin exerts its cytotoxic effects by intercalating into DNA, inhibiting DNA topoisomerase II, and generating free radicals, leading to DNA damage and cell death. The DCB microspheres provide localized and sustained release of epirubicin to the tumor.

Other names: drug-eluting bead transbronchial artery chemoembolization

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on D-BACE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-BACE.

Explore the full profile